Amneal Pharmaceuticals, Inc. annual report, FY2020

Amneal Pharmaceuticals, Inc. — FY2020 Form 10-K

Reporting period: Fiscal year ended December 31, 2020. Although the request refers to 2020 Q4, this filing reports full-year results; it does not provide a standalone Q4 financial summary. Amneal develops, manufactures, markets and distributes generic and branded pharmaceuticals. FY2020 included AvKARE and R&S results from their January 31, 2020 acquisition, so comparisons with 2019 are not fully like-for-like.

Financial performance and liquidity

Metric	FY2020	FY2019
Net revenue	$1.993 billion	$1.626 billion
Gross profit / margin	$628 million / 32%	$353 million / 22%
Operating income (loss)	$91 million	$(249) million
Net income (loss)	$69 million	$(604) million
Net income (loss) attributable to Amneal, Inc.	$91 million	$(362) million
Operating cash flow	$379 million	$2 million

• Revenue increased 23%, primarily reflecting $294 million of AvKARE revenue and $214 million from Generics product launches; competition and divestitures partly offset growth. The filing attributes $110 million of income-tax benefit to CARES Act NOL carrybacks, and reports collection of approximately $110 million in related cash, including interest.
• FY2020 operating cash flow also reflected improved operations and collections, partly offset by inventory investment. Investing cash outflow was $318 million, largely due to acquisitions; financing cash inflow was $132 million.
• Cash and cash equivalents were $341 million, working capital $875 million, and total assets $4.006 billion at year-end. The revolving credit facility had $495 million available and no balance outstanding.
• Total debt was $2.806 billion, including a $2.632 billion term loan and $173 million Rondo term loan; long-term debt, net, was $2.735 billion. Debt is predominantly variable-rate, with a $1.3 billion interest-rate hedge. The company expected 2021 term-loan principal payments of $41 million and interest of $112 million, plus Rondo principal of $9 million and interest of $6 million.

Segments and changes versus prior year

• Generics: Revenue was $1.343 billion, up 3%; operating income was $189 million versus a $133 million loss. Higher gross profit reflected lower impairment charges, reduced transition-agreement and inventory costs, and improved plant utilization, partly offset by competitive erosion in products including levothyroxine and diclofenac gel.
• Specialty: Revenue was $356 million, up 12%; operating income was $57 million versus $43 million. Excluding the mid-2019 reclassification of oxymorphone, revenue grew 3%. Rytary and Unithroid volumes helped, while COVID-19 affected Emverm sales. R&D spending increased with IPX203 development and milestone payments.
• AvKARE: Acquired in January 2020, it contributed $294 million of reported revenue and an operating loss of $8 million. Its revenue is not directly comparable with 2019, when the segment was not reported.
• Consolidated operating results improved in part because impairment charges declined to $37 million from $173 million. FY2020 still included $9 million of acquisition, transaction and integration expenses. Net other expense was $127 million, including $146 million of net interest expense.

Outlook, risks and unusual items

• The filing gives no formal revenue or earnings guidance. Management estimated 2021 capital expenditures of $60–$70 million and expected to close its Kashiv Specialty Pharmaceuticals acquisition in the first half of 2021. The announced terms included $70 million at closing, $30 million one year after signing, up to $8 million in milestone payments, and product royalties; management expected to use cash on hand.
• Management said COVID-19 caused lost sales and supply/manufacturing interruptions in New York, New Jersey and India. Operations had returned to around pre-pandemic levels, but further disruptions could affect 2021 results and cash flows.
• Key business risks include generic price erosion and competition, dependence on a small number of products, and customer concentration: three wholesalers accounted for approximately 83% of FY2020 gross product sales. The company also cites supply-chain and sole-source supplier risks, regulatory and product-quality risks, and substantial debt and variable interest-rate exposure.
• Material legal matters include generic-drug pricing antitrust litigation and government investigations, opioid litigation (approximately 850 federal MDL cases and approximately 120 state cases at year-end), and ranitidine and metformin litigation. The company said outcomes and potential losses were uncertain and generally could not be estimated; it stated it did not then expect the matters, based on information available, to have a material adverse effect in the aggregate.
• A $423 million valuation allowance reduced net deferred tax assets to zero. No tax receivable agreement (TRA) liability was accrued at year-end, but approximately $206 million could become payable if the relevant tax benefits become realizable; change-of-control or early-termination provisions could accelerate payments.
• A material weakness in controls over vendor bank-account changes, identified during 2020, was reported remediated by year-end; the company said it caused no financial loss or material financial-statement impact. Management and the auditor excluded AvKARE and R&S controls from their year-end assessment because they were recently acquired; those businesses represented approximately 15% of consolidated revenue.
• Other notable items include $37 million of intangible-asset impairment charges and a prior-year $193 million gain from reversal of an accrued TRA liability. The company reported no goodwill impairment in 2020. Zomig Spray market exclusivity was expected to end May 29, 2021.

Most important facts for investors to verify

• How much of the revenue and operating improvement is sustainable and organic after separating AvKARE acquisition effects, new launches, and nonrecurring tax benefits?
• Whether product-level price erosion, customer concentration, and sales-allowance estimates—including $175 million of returns reserves and $131 million of Medicaid and commercial rebate reserves—change materially.
• Debt service capacity under variable rates, the LIBOR transition, planned 2021 payments, and the liquidity impact of acquisitions and any future TRA obligations.
• The status, potential exposure and reserve adequacy for antitrust, opioid, government-pricing, and product-liability matters; the filing does not provide clear estimated loss ranges for many proceedings.
• Whether the remediated controls remain effective and how the acquired AvKARE and R&S businesses perform once included in the company’s control assessment.